Raised long-term growth outlook reflects specialty-led execution, despite near-term oncology, debt, and portfolio-review headwinds.
| Quarter | Q4 FY25 |
|---|---|
| Length | 62 minutes |
| EPS | $3.84 |
| EPS consensus | $3.79 |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q3 FY26 · Q1 FY26 · Q3 FY25 · Q2 FY25 · Q1 FY25 · Q4 FY24
All COR earnings · Back to COR overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.